Zafgen Inc (NASDAQ:ZFGN) shares saw strong trading volume on Friday . 828,393 shares changed hands during trading, an increase of 125% from the previous session’s volume of 368,411 shares.The stock last traded at $0.71 and had previously closed at $0.71.
A number of equities research analysts recently weighed in on the company. Wedbush cut Zafgen from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $6.00 to $0.78 in a report on Friday, September 6th. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Sunday, September 8th. JMP Securities cut Zafgen from an “outperform” rating to a “market perform” rating in a report on Thursday, September 5th. ValuEngine raised Zafgen from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Roth Capital cut Zafgen from a “buy” rating to a “neutral” rating in a report on Friday, September 6th. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Zafgen has an average rating of “Hold” and a consensus price target of $6.05.
The stock has a market capitalization of $26.53 million, a price-to-earnings ratio of -0.37 and a beta of -0.55. The company has a current ratio of 6.98, a quick ratio of 6.98 and a debt-to-equity ratio of 0.25. The stock has a fifty day moving average of $0.75 and a two-hundred day moving average of $1.57.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.06. Equities analysts expect that Zafgen Inc will post -1.15 earnings per share for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in ZFGN. Renaissance Technologies LLC boosted its position in Zafgen by 71.2% in the 2nd quarter. Renaissance Technologies LLC now owns 1,678,300 shares of the biopharmaceutical company’s stock valued at $1,997,000 after buying an additional 697,724 shares during the last quarter. AWM Investment Company Inc. boosted its position in Zafgen by 32.4% in the 2nd quarter. AWM Investment Company Inc. now owns 1,857,171 shares of the biopharmaceutical company’s stock valued at $2,210,000 after buying an additional 454,874 shares during the last quarter. Worth Venture Partners LLC bought a new position in Zafgen in the 2nd quarter valued at $316,000. Acadian Asset Management LLC bought a new position in Zafgen in the 1st quarter valued at $389,000. Finally, Paloma Partners Management Co bought a new position in Zafgen in the 2nd quarter valued at $163,000. Hedge funds and other institutional investors own 80.72% of the company’s stock.
About Zafgen (NASDAQ:ZFGN)
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
See Also: Call Option Volume
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.